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Abstract
Introduction
Purpose: To assess effectiveness of the XEN45 gel stent after nasal superior implantation compared to nasal inferior implantation.
Methods: Retrospektive analysis of 152 eyes with XEN45 gel stent implantation in the nasal superior quadrant (Group A, n=56) or in 
the nasal inferior quadrant (Group B, n=96).
Results: Mean IOP decreased from 33.6± 8.8 mmHg preoperatively to 14.6± 3.2 mmHg at Month 12 in Group A (p <0.05) and from 
32.6± 10.1 mmHg to 14.1± 4.3 mmHg in Group B (p <0.05). Medication usage reduced from 3.2± 0.9 medications at baseline to 0.3± 
0.7 medications at Month 12 in Group A (p<0.05) and from 3.1± 1.0 to 0.3± 0.7 in Group B (p<0.05). At Month 3, a significantly lower 
mean IOP (p=0.023; Mann-Whitney-U-test) and medication usage (p=0.021; Welch`s t-test) were observed in Group A. At all other 
visits no significant differences were observed (p>0.05). Needling was required in 45% of eyes in Group A and in 27% of Group B 
(p=0.031; Fisher`s exact test). A second XEN45 gel stent was implanted in 4 eyes of Group A and 7 eyes of Group B. Hypotony (IOP ≤ 
6 mmHg) was observed in 3 eyes of Group A and 4 eyes of Group B. All cases resolved spontanously.
Conclusion: Overall, the 1-year results of our retrospective analysis show that implantation of the XEN45 gel stents in the nasally 
inferior quadrant is as effective as implantation in the superior nasal quadrant and results in significantly reduced IOP and medica-
tion usage in glaucoma patients.
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Glaucoma is one of the main causes of blindness, affecting more 
than 64 million people worldwide. [1] Reduction oft he intraocular 
pressure (IOP) is the only recognized treatment strategy to prevent 
further damage to the optic nerve and stop or at least slow the pro-
gression of the disease. [2] Therapy options include hypotensive 
medication, laser procedures and glaucoma drainage surgery. [3,4] 
Despite the proven efficacy and safety of hypotensive drugs, local 
and systemic side effects as well as complex treatment regimens 
can adversely affect adherence and thus limit their efficacy. [5,6] 
In patients whose IOP is not sufficiently controllable with two 
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The XEN45 gel stent is commonly implanted in the superonasal 
quadrant in order to spare the superior area which is usually cho-
sen for trabeculectomy. Even if this approach is usually successful, 
in some cases the filtering bleb may extend into the superior region 
possibly leading to changes in the conjunctiva that might impede fu-
ture trabeculectomy. An implantation of the XEN45 gel stent in the 
nasally inferior quadrant might therefore be advantageous for sev-
eral reasons. First of all, the entire superior area would remain com-
pletely untouched, thus facilitating future trabeculectomies. Second, 
the inferior quadrant is more easily accessible during surgery, espe-
cially in high cheekbones, which in some cases can impede access 
with the injector to the superior quadrant. Finally, implantation in 
the inferior quadrant is conveniently possible without adapting the 
typical set-up of most operating room with the surgeon sitting at 
12 o’clock. However, to the best of out knowledge, no comparative 
analysis has yet been published clarifying whether the location of 
the implant affects the effectiveness of the XEN45 gel stent.
This is a retrospective analysis of consecutive glaucoma patients 
who received a XEN45 gel implant between March 2014 and June 
2015 at the Department of Ophthalmology, Goethe-University, 
Frankfurt, Germany. The data documentation and retrospective 
analysis was approved by the local Ethics Committee and adhered 
to the tenets of the Declaration of Helsinki.
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Medical records of 152 glaucoma patients with available 12 months 
follow-up data were included in this analysis.  Patients had suffered 
from an inadequately controlled IOP and had been referred to our 
Department with a request for surgical glaucoma therapy. In case 
of a healthy, free and mobile conjunctiva in the target quadrant and 
lack of active inflammation, patients were considered eligible for 
XEN45 gel stent implantation. Patients with angle-closure glau-
coma, active neovascular glaucoma, conjunctival scarring, or other 
conjunctival pathologies in the target quadrant, pregnancy, age < 
18 years, condition after pars plana vitrectomy, flat anterior cham-
ber and narrow chamber angle were not considered eligible. Prior 
to XEN45 implantation a complete ophthalmic examination includ-
ing gonioscopy had been performed. At day 1, week 1, and months 
1, 3, 6, and 12 postoperative examinations were performed. At 
each visit, slit-lamp examination, gonioscopy, and IOP assessment 
by Goldmann applanation tonometry were carried out. Moreover, 
the number of medications, needling, second filtrating surgery and 
adverse events were documented.
All implantations were performed as a stand-alone procedure by 
one single surgeon (FHH) following a standardized implantation 
technique which has been described in detail in a recent publica-
tion. [20] In brief, the XEN45 was implanted under peribulbar an-
esthesia using an ab interno approach. At first, a volume of 0.1 ml 
of MMC solution (0.01% mitomycin C, a total dose of 10µg) was in-
jected subconjunctivally in the nasal superior quadrant to prevent 
further scarring of the conjunctiva. After the anterior chamber was 
filled with a medium grade viscoelastic device, the preloaded injec-
tor needle was then inserted through a 1.2 mm corneal paracente-
sis incision opposite the site of desired implantation. The needle 
was then directed across the anterior chamber and the injector tip 
was used to penetrate through the chamber angle above trabecular 
meshwork and the sclera at least 3 mm in length in order to place 
the implant properly.  After careful removal of viscoelastic and hy-
dration of paracenteses the eye was covered with a patch.
Methodsmedications, surgical options may be taken into account. [4] Trab-
eculectomy, still the gold standard of surgical glaucoma treatment, 
demonstrates excellent efficacy but requires a strict postoperative 
follow-up and has a less than ideal risk profile. [7] Several minimally 
invasive glaucoma surgery (MIGS) devices which can be implanted 
ab interno have been developed with the aim to offer a safer, less in-
vasive means of reducing IOP than traditional surgery.[8] Of these, 
the XEN45 gel implant (XEN45) (Allergan, Dublin, Ireland) creates 
a permanent drainage path from the anterior chamber into the sub-
conjunctival space, thus bypassing the natural drainage pathways 
often obstructed in glaucoma patients. [9-11]  It consists of hydro-
philic gelatine glutaraldehyde, has good biocompatibility and toler-
ability and is not degradable. [10, 12] The dimensions of the tube (6 
mm length; 45 µm inner diameter) were chosen in accordance with 
Hagen Pouiselle’s law to maximize long-term drainage of aqueous 
humor while minimizing the risk of hypotension. [10, 12-14] Clini-
cal studies have shown that the XEN45 leads to an effective IOP and 
drug reduction and is associated with a good safety profile. [15-22] 
The aim of this retrospective study was to evaluate the IOP lowering 
and medication reduction effect after nasal superior implantation 
of the XEN45 gel stent implant compared to a nasal inferior implan-
tation. Our hypothesis was that nasal inferior implantation of the 
XEN45 gel stent is non-inferior to nasal superior implantation in 
terms of sucess rate, IOP decrease and medication reduction.
Patients and Assessments
Surgical procedure
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Data was statistically analysed using SPSS Statistics Version 24.0. 
(IBM 2016). [23] For the comparative analysis, two groups accord-
ing to the implantation site (Group A: superior nasal; Group B: in-
ferior nasal) were defined. Effectiveness variables were mean IOP, 
mean number of hypotensive medication and needling rate at each 
follow-up visit as well the proportion of patients achieving a tar-
get IOP of ≤ 18 mmHg, ≤ 15 mmHg, and ≤ 13 mmHg at 12 months. 
Moreover success rates after one year were calculated according 
to the following definitions: „qualified success“ was defined as IOP 
reduction of at least 20% and an IOP value below 18 mmHg with 
and without medication. Complete success” was defined as an IOP 
reduction of at least 20% and an IOP value below 18 mmHg with-
out medication. Safety outcomes included hypotony rate (IOP ≤ 6 
mmHg) as well as intra- and postoperative complications.
Data were presented as mean and standard deviation, unless oth-
erwise indicated. Baseline IOP was the IOP measured at the preop-
erative visit on medications and the IOP measured at each visit was 
then used to calculate the change from baseline. In order to com-
pare pre- and postoperative values, the t-test was used. Also, the 
Wilcoxon sign rank test was used for determining statistical signifi-
cance within a group (p < 0.05 considered statistically significant). 
For determining statistical significance between both groups, t-test 
for two independent samples (p < 0.05 considered statistically sig-
nificant). Chi-square tests were performed in all other cases (p < 
0.05 considered statistically significant).
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Postoperatively, topical antibiotics were given 4 times daily for 10 
days in combination with steroids 6 times daily and tapered out 
over 6 weeks. Anti-glaucoma medication was given until surgery 
and was completely stopped after the implantation of the gel im-
plant; there was no wash-out phase. At every visit, IOP was assessed 
and if IOP was elevated, additional anti-glaucoma medication or 
secondary intervention were given at the discretion of the surgeon. 
In case of conjunctival scarring and bleb failure due to Tenon’s cyst 
formation, a needling procedure was performed under microscopic 
view in the operating room. The needling technique has recently 
been described in detail. [20] The administration of additional 
drugs during the needling was considered on a case-by-case basis. 
Only in cases of pronounced fibrosis (approx. 10% of cases) 10 µg 
mitomycin C was injected during needling, while in eyes with cystic 
fibroses no additional drugs were used.
Statistical Methods
Overall, medical records of 152 glaucoma eyes with a mean age of 
68.7 ± 14.5 years were analysed. The XEN45 gel stent was implant-
ed in the nasal superior quadrant in 56 eyes (Group A) and in the 
nasal inferior quadrant in 96 eyes (Group B). Demographics and 
baseline ocular parameters of both groups are presented in Table 1, 









Age (years), mean ± 
SD (range)
67.8 ± 15.6 69.2 ± 13.9 p = 0.76
(28-91) (28 - 91)
Gender, n (%)*
Male 27 (48.1) 34 (35.1) p = 0.16
Female 29 (51.9) 62 (64.9)
Operated Eye, n (%)*
OD (right eye) 27 (48.1) 48 (50.0) p = 0.87
OS (left eye) 29 (51.9) 48 (50.0)
Cup to Disc Ratio, 
mean ± SD (range)
0.8 ±0.1 0.8 ± 0.1 p = 0.93
(0.4-1.0) (0.5-1.0)
IOP (mmHg), mean ± 
SD (range)
33.6 ± 8.8 32.6 ± 10.1 p = 0.57
(20-55) (18–65)
Number of medica-
tion, mean ± SD 
(range)
3.2 ± 0.9 3.1 ± 1.1 p = 0.87
(1 - 5) (0 - 5)
Table 1: Demographics and baseline ocular parameters.
IOP: intraocular pressure; SD: standard deviation; *percentages 
refer to the respective group (with/without prior intervention); § 
Fisher`s exact test was performed to compare both groups; P-value 
<0.05 was determined to be statistically significant.
From the first postoperative day until the end of the one-year fol-
low-up period, at each visit the mean IOP was significantly reduced 
from baseline in both groups (Figure 1). In Group A (nasal superior 
implantation), the mean IOP decreased significantly by 55% from 
preoperatively 33.6 ± 8.8 mmHg to 14.6 ± 3.2 mmHg at 12 months 
postoperatively (p= 0.000; Wilcoxon test), while in Group B (nasal 
inferior implantation) a mean IOP reduction by 54% from 32.6 ± 
10.1 mmHg at baseline to 14.1 ± 4.3 mmHg at one year postopera-
tively was observed (p= 0.000; Wilcoxon test). The t-test analysis 
revealed a statistically significant difference between both groups 
at Week 1 (p=0.009) and Month 3 (p=0.031). Non-parametric tests 
Journal of Ophthalmology and Vision Research
Citation:  Fritz H. Hengerer, Gerd Auffarth and Ina Conrad-Hengerer. (2019). Nasal Superior Versus Nasal Inferior Implantation of the 
Xen45 Gel Stent – One Year Results. Journal of Ophthalmology and Vision Research 1(1).
Page 4 of 7
confirmed a statistically significant lower IOP in eyes with nasal 
inferior XEN gel stent implantation as compared to eyes with su-
peronasally located implants at Month 3 (p=0.023; Mann-Whitney-
U-test). At all other visits, no significant differences in mean IOP 
were found between the two groups (p > 0.05; Mann-Whitney-U-
test) (Figure 1). Regarding the proportion of eyes achieving target 
pressure values of 18 mmHg, 15 mmHg and 13 mmHg at one year 
postoperatively no significant differences were observed between 
both groups (p > 0.05; Chi square test) (Figure 2).
Figure 1: Mean IOP of eyes with XEN45 gel stent implantation 
in the nasal superior quadrant (n=56) and in the nasal inferior 
quadrant (n=96) at each study visit. Error bars indicate SD for the 
mean. Within each group, the mean IOP was significantly reduced 
from baseline at any visit during the follow-up period (p= 0.000; 
Wilcoxon test). While at month 3 a significant difference in mean 
IOP was detected between both groups (p=0.023; Mann-Whitney-
U-test), no significant differences were observed at any other 
study visit (p > 0.05; Mann-Whitney-U-test).
Figure 3: Mean number of anti-glaucoma medications of eyes 
with XEN45 gel stent implantation in the nasal superior quadrant 
(n=56) and in the nasal inferior quadrant (n=96) at each study visit. 
In each group the mean number of medication was significantly re-
duced from baseline at all visits (p= 0.000; Wilcoxon test). Between 
groups, significant differences were observed at Month 3 (p=0.021; 
Welch`s t-test). Error bars indicate SD for the mean.
While in Group A (nasal superior implantation) 79% of eyes 
(44/56) had been on three or more hypotensive medications at 
baseline, this was the case in one eye at 12 months postoperatively. 
In Group B (nasal inferior implantation), three or more medica-
tions were required in 76% of eyes (73/96) preoperatively and in 
no eye at the end of the follow-up period (Figure 4 a, b). One year 
after XEN45 gel stent implantation, 86% of eyes (48/56) in Group 
A and 79% of eyes (76/96) in Group B were completely off drops 
(Figure 4b).
Figure 2:  Proportion of eyes reaching a certain target pressure 
at 12 months postoperatively. Comparison of eyes with nasally 
superior (n=56) or nasally inferior implantation site (n=96). No 
significant differences were detected between groups.
Also, mean number of hypotensive medications was significantly 
reduced at every visit from the first postoperative day until Month 
12 in both groups (Figure 3). While in Group A (nasal superior im-
plantation) a significant reduction was observed from in mean 3.2 
± 0.9 medications at baseline to 0.3 ± 0.7 medications at 12 months 
postoperatively (p= 0.000; Wilcoxon test), in Group B (nasal infe-
rior implantation) the mean number of medications had decreased 
from 3.1 ± 1.0 to 0.3 ± 0.7 (p= 0.000; Wilcoxon test). At Month 3, 
the required mean number of medications was significant lower in 
Group A as compared to Group B (p=0.021; Welch`s t-test), while at 
all other visits no significant differences between the groups were 
observed (p > 0.05; Welch`s t-test) (Figure 3).
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Figure 4: Proportion of eyes requiring 0 - 5 anti-glaucoma medica-
tions at a) baseline and b) at 12 months postoperatively. Compari-
son of eyes with XEN45 gel stent implantation in the nasal superior 
quadrant (n=56) and in the nasal inferior quadrant (n=96). 
Qualified success, i.e. IOP reduction of at least 20% and an IOP value 
below 18 mmHg without or with medication was achieved in 64% 
(36/56) of eyes in Group A and 77% (74/96) of eyes in Group B at 
12 months postoperatively. Complete success, i.e. an IOP reduction 
of at least 20% and an IOP value below 18 mmHg without medica-
tion, was experienced by 46% (26/56) of eyes in Group A and by 
60% (58/96) of eyes in Group B one year after XEN45 implanta-
tion. However, the differences between the two groups regarding 
qualified and complete success were statistically not significant 
(p=0,095 and p=0.077; Log Rank).
In order to enhance outflow, needling of the bleb was required in 
45% (25/56) of eyes in Group A (nasal superior implantation) and 
27% (26/96) of eyes in Group B (nasal inferior implantation) with-
in 12 months (p=0.031; Fisher`s exact test), with most needlings 
being performed beetween Week 1 and Month 3 in both groups. 
During the follow-up phase, 4 eyes of Group A (7.2%) and 7 eyes of 
Group B (7.3%) presented with uncontrollable IOP and received a 
second XEN45 gel stent implant. 
Hypotony (IOP ≤ 6 mmHg) was observed in 3 eyes of Group A 
(5.3%) and 4 eyes of Group B (4.2%) at Month 1 postoperatively 
(p > 0.05). At Month 3, all hypotony cases of Group B had spon-
tanously resolved, while in Group A two cases were still present but 
were resolved until Month 6. Visual acuity threatening complica-
tions related to hypotony such as choroidal effusion or hemorrhage, 
choroidal detachment, or macular folds were not observed in either 
group. In addition, no cases of corneal alteration, migration or ex-
posure of the implant, wound leakage or endophthalmitis occurred 
in either group.
Several studies have shown that ab-interno placement of the XEN45 
gel stent offers a minimally invasive, effective surgical treatment op-
tion for open angle glaucoma.[15-22] Usually, the XEN45 gel stent is 
implanted superionasally, however, its positioning in the nasally in-
ferior quadrant might completely spare the superior area for future 
trabeculectomies and might facilitate the implantation process. The 
results of our retrospective comparative analysis confirmed our hy-
pothesis that nasal inferior implantation of the XEN45 gel stent is 
non-inferior to nasal superior implantation in terms of sucess rate, 
IOP decrease and medication reduction.
One-year after XEN45 gel stent implantation, success rates were 
statistically not significantly different between both groups, with 
64% of eyes with nasal superior implantation and 77% of eyes 
with nasal inferior implantation reaching qualified success (i.e. 
IOP reduction of at least 20% and an IOP value below 18 mmHg 
without and with medication). Regardless of the implantation site, 
mean IOP was effectively reduced from over 30 mmHg at baseline 
to under 15 mmHg at 12 months and dependance on hypotensive 
medication was effectively reduced from at least 3 medications to 
0.3 medications. While preoperatively the vast majority of eyes 
were on three or more medications, one year postoperatively 86% 
of eyes with nasal superior implantation and 79% of eyes with na-
sal inferior implantation were completely off drops. These results 
are consistent with those of other studies and show that the XEN45 
stent IOP can effectively reduce and hypotensive drugs in glaucoma 
patients regardless of its implantation site. In view of these data, 
it seems reasonable to consider XEN45 gel stent implantation at 
an earlier point in glaucoma therapy in order to ensure long-term 
therapeutic success in glaucoma patients with insufficient adher-
ence or side effects of medication. It is well known that topical and 
systemic side effects, difficulties in administering the drug, and the
Discussion
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complexity of drug regimens can considerably affect patients` ad-
herence with their therapy. In this context is also noteworthy a 
recent study showing that about one third of prescriptions in Ger-
many remain unfulfilled.[6, 24, 25] 
Limitations of the current study include a retrospective design and 
a limited duration of follow up. Data were collected from a single 
center and there might be a a certain degree of selection bias as the 
decision to offer XEN45 gel stent implantation was determined by 
one surgeon, without strict inclusion or exclusion criteria. A pro-
spective study with longer follow-up and including anatomically 
examination of the bleb would be required to assess whether a na-
sally inferior is advantageous to nasally superior implantation of 
the XEN45 gel implant.
Overall, the 1-year results of our retrospective analysis show that 
implantation of the XEN45 gel stents in the nasally inferior quad-
rant is at least as effective in reducing IOP and medication usage 
as implantation in the superior nasal quadrant. Nasally inferior im-
plantation may be associated with a lower needling rate.
However, even though one year after XEN implantation there were 
no statistically significant differences regarding IOP decrease and 
medication reduction between the two groups, we observed sig-
nificant differences in the early course of the follow-up period. At 
Month 3, both the mean IOP and the required mean medication 
were significantly lower in eyes with a nasally inferior implanta-
tion site. At the same time, needling, which was usually performed 
within the first three months, was significantly more frequently 
required in eyes with a superior nasally implanted XEN gel stent. 
This may suggest that in eyes with nasal inferior XEN45 gel stent 
implantation the resulting bleb allows a more pronounced aque-
ous humor outflow without further enhancement within the early 
postoperative period. At the same time, hypotension occurred only 
numerically and to a comparable extent in both groups indicating 
that the XEN45 stent, following the principles of the Hagen-Poi-
seuille law, is associated with a low risk of hypotony.
We do not yet have a reliable explanation why in the group of na-
sally inferior implanted XEN45 implants IOP and medication usage 
were lower at Month 3 and at the same time needling was required 
less often. One possible explanation would be that in our analy-
sis such eyes were incidentally treated with a nasally inferior im-
planted XEN45 gel stent, which would not have required needling 
anyway. In this case, the implantation site would have no effect 
on the early postoperative response.  In this context, it has to be 
mentioned that in a retrospective analysis by Tan et al in which the 
XEN45 stent was superonasally implanted in 39 eyes, no needling 
was required in half of the cases.[22] However, no baseline param-
eter could be determined to which a higher needling rate might 
be attributable. Another explanation would be that possibly the 
lower tension of the lower lid could be a reason for a more pro-
nounced outflow after nasal inferior implantation of the XEN45 gel 
stent and a reduced needling rate. We postulate that the increased 
tension of the upper eyelid might lead to a greater flattening dur-
ing the healing process resulting in a more pronounced fibrosis of 
the bleb in the early postoperative phase. If this were the case, a 
nasally inferior implantation of the XEN gel stent could be advanta-
geous especially in eyes with high tension of the upper eyelid or 
in deep-set eyes. However, this assumption will have to be further 
investigated in studies also examining bleb anatomy.
Conclusion
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